Celgene Corporation (NASDAQ: CELG)

DEFENDANT NAME: Celgene Corporation
STOCK SYMBOL: NASDAQ: CELG
CASE NUMBER:
COURT: U.S. District Court for the District of New Jersey
PRACTICE AREA: Investor Fraud
STATUS: Investigation
CLASS PERIOD: January 12, 2015 - February 27, 2018
LEAD PLAINTIFF DEADLINE: May 29, 2018
DATE FILED:
COURT LOCATION:
RELATED DOCUMENTS:
CONTACT:
510-725-3000 CELG@hbsslaw.com
Hagens Berman Sobol Shapiro LLP reminds investors in Celgene Corporation (NASDAQ: CELG) of the May 29, 2018 Lead Plaintiff deadline in the securities class action pending the U.S. District Court for the District of New Jersey.

If you purchased or otherwise acquired shares of CELG between January 12, 2015 and February 27, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information, contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing CELG@hbsslaw.com.

Celgene acquired a late-stage developmental drug (“GED-0301”) from Nogra Pharma Limited in April 2014.

On October 19, 2017 Defendants announced Celgene would abandon GED-0301, discontinue ongoing trials, and record a $1.6 billion impairment charge with certain offsets.

This news drove the price of Celgene shares down $14.63, or about 11%, to close at $121.33 on October 20, 2017.

Then, on February 27, 2018, Defendants announced the U.S. Food and Drug Administration sent the Company a Refusal to File letter for its new drug application for another important drug known as Ozanimod.  One analyst asked “How many self-inflicted wounds are excusable?”  The analyst reportedly stated Celgene “clearly made a decision to file this application at risk, despite late information that might have been more thoroughly disclosed and explored in the application, had the filing been postponed by a few months.”

This news drove the price of Celgene shares down $8.66, or over 9%, to close at $87.12 on February 28, 2018.

Shortly afterwards, on April 2, 2018, Defendants announced Celgene’s President and Chief Operating Officer (Scott A. Smith) immediately left the Company.

“Celgene investors have suffered enormous losses,” said Hagens Berman partner Reed Kathrein.  “We’re focused on Defendants’ statements reassuring investors about their steps to replace anticipated lost revenues from the Company’s multiple myeloma drug, including commercialization of GED-0301 and Ozanimod.”

Whistleblowers:  Persons with non-public information regarding Celgene should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email CELG@hbsslaw.com.


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Contact:

Please fill out the form below and we will get back to you as soon as we can.
 
*
*
*
*
*
*
File Upload *
Additional Information *
Send me: *
*
*
*
 

Case videos

Case Gallery

Case Timeline

04/06/18: Investigation